A5031954491- Nanoparticle-Based Drug Delivery
- Autophagy in Disease and Therapy
- RNA Interference and Gene Delivery
- Nanoplatforms for cancer theranostics
- Estrogen and related hormone effects
- Nanoparticles: synthesis and applications
- Pancreatic and Hepatic Oncology Research
- Drug Transport and Resistance Mechanisms
- Physiological and biochemical adaptations
- Retinoids in leukemia and cellular processes
- Lipid Membrane Structure and Behavior
- Advanced Drug Delivery Systems
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Computational Drug Discovery Methods
- Pharmacogenetics and Drug Metabolism
- Aquaculture Nutrition and Growth
- Drug-Induced Hepatotoxicity and Protection
- Sphingolipid Metabolism and Signaling
- Photodynamic Therapy Research Studies
- Neuroendocrine Tumor Research Advances
- Advanced biosensing and bioanalysis techniques
- Drug Solubulity and Delivery Systems
- Graphene and Nanomaterials Applications
- Crustacean biology and ecology
Frederick National Laboratory for Cancer Research
2016-2025
National Cancer Institute
2006-2025
Leidos (United States)
2015-2025
Science Applications International Corporation (United States)
2007-2023
Northwestern University
2010-2023
Leidos Biomedical Research Inc. (United States)
2016-2021
University of North Carolina at Chapel Hill
2005-2019
National Institutes of Health
2008-2018
Center for Veterinary Medicine
2016
The University of Texas Southwestern Medical Center
2010
The Nanotechnology Characterization Laboratory's (NCL) unique set-up has allowed our lab to handle and test a variety of nanoparticle platforms intended for the delivery cancer therapeutics and/or imaging contrast agents. Over last six years, NCL characterized more than 250 different nanomaterials from 75 investigators. These submitted stem range backgrounds experiences, including government, academia industry. This given valuable opportunity observe trends in safety biocompatibility, as...
We address an outstanding issue associated with the biocompatibility of gold nanorods (GNRs), a promising agent for biomedical imaging and theragnostics. GNRs are typically prepared in presence cetyltrimethylammonium bromide (CTAB), cationic surfactant whose rigorous removal is necessary due to its cytotoxicity membrane-compromising properties. CTAB-stabilized can be partially purified by treatment polystyrenesulfonate (PSS), anionic polyelectrolyte often used as surrogate peptizing agent,...
Quantum dots (QDs) are being investigated as novel in vivo imaging agents. The leaching of toxic metals from these QDs biological systems is great concern. This study compared the cytotoxic mechanisms two QD species made different core materials (cadmium selenide [CdSe] vs. indium gallium phosphide [InGaP]) but similar sizes (5.1 3.7 nm) and surface compositions (both ZnS capped, lipid-coated pegylated). CdSe was found to be 10-fold more porcine renal proximal tubule cells (LLC-PK1) than...
Interpretation of nanoparticle PK results can be markedly influenced by differing metrics selected.
The clinical success of arsenic trioxide (As(2)O(3)) in hematologic malignancies has not been replicated solid tumors due to poor pharmacokinetics and dose-limiting toxicity. We have developed a novel nanoparticulate formulation As(2)O(3) encapsulated liposomal vesicles or "nanobins" [(NB(Ni,As)] overcome these hurdles. postulated that nanobin encapsulation would improve its therapeutic index against clinically aggressive tumors, such as triple-negative breast carcinomas.
Ceramide, an endogenous sphingolipid, has demonstrated antieoplastic activity in vitro and vivo. However, the chemotherapeutic utility of ceramide is limited because its insolubility. To increase solubility ceramide, liposomal delivery systems have been used. The objective present study was to characterize pharmacokinetics tissue distribution C6-ceramide control (non-C6-ceramide) nanoliposomes rats, using [<sup>14</sup>C]C6-ceramide [<sup>3</sup>H]distearylphosphatidylcholine (DSPC) as...
The objective of this study was to compare the pharmacokinetics and metabolism polymeric nanoparticle-encapsulated (nanocurcumin) solvent-solubilized curcumin formulations in Sprague–Dawley (SD) rats. Nanocurcumin is currently under development for cancer therapy. Since free, unencapsulated rapidly metabolized excreted rats, upon intravenous (i.v.) administration nanocurcumin only can be detected plasma samples. Hence, second utilize metabolic instability assess vivo drug release from...
Nanotechnology is the control and manipulation of materials in size range 1-100 nm. Coupled with increasing research into potential beneficial applications nanotechnology, there an urgent need for study possible health risks. Several researchers, including those our laboratory, have demonstrated elevated levels autophagic vacuoles upon exposure cells to certain nanomaterials, carbon- metal-based nanoparticles. While this apparent increase activity may be appropriate cellular response toward...
The physicochemical characteristics, in vitro properties, and vivo toxicity efficacy of a third generation triazine dendrimer bearing approximately nine 2 kDa polyethylene glycol chains twelve ester linked paclitaxel groups are reported. hydrodynamic diameter the neutral construct varies slightly with aqueous solvent ranging from 15.6 to 19.4 nm. Mass spectrometry light scattering suggest radically different molecular weights former ∼40 mass consistent expectation, latter 400 decameric...
We developed a pegylated liposome formulation of dissociable salt nitrogen-containing bisphosphonate, alendronate (Ald), coencapsulated with the anthracycline, doxorubicin (Dox), commonly used chemotherapeutic agent. Liposome-encapsulated ammonium Ald generates gradient driving Dox into liposomes, forming that holds both drugs in water phase. The resulting (PLAD) allows for high-loading efficiency Dox, comparable to clinically approved liposomal sulfate (PLD) and is very stable plasma...